|
Guerbet Group is one of Europe's leading makers of contrast agents used in medical imaging. Most of the company's products, such as Xenetix, Hexabrix, and Dotarem, are substances that are injected into the body to make internal organs visible during X-ray and magnetic resonance imaging (MRI) examinations. Subsidiary Simafex manufactures specialty chemicals for use in pharmaceuticals. Guerbet has operations in some 15 countries and is targeting growth in the US. Marcel Guerbet, grandfather of chairman Michel Guerbet, developed the first iodinated contrast agent around the turn of the century; his descendants control the company.
|
| | | Contact Information | |
Address: |
15, rue des Vanesses
93420 Villepinte, France
| | Phone: | +33-1-45-91-50-00 | | Fax: | +33-1-45-91-51-99 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 452.10 M | | Revenue Growth (1 yr): | 0.50% |
|
|
Key People
| | • |
Honorary Chairman:
Michel Guerbet
| | • |
Chairman of the Executive Board and CEO:
Philippe Décazes
| | • |
CFO:
Philippe Barthelet
|
|
|
